169 related articles for article (PubMed ID: 14688112)
1. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.
Balmer P; Falconer M; McDonald P; Andrews N; Fuller E; Riley C; Kaczmarski E; Borrow R
Infect Immun; 2004 Jan; 72(1):332-7. PubMed ID: 14688112
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.
Borrow R; Southern J; Andrews N; Peake N; Rahim R; Acuna M; Martin S; Miller E; Kaczmarski E
Vaccine; 2001 Apr; 19(23-24):3043-50. PubMed ID: 11311998
[TBL] [Abstract][Full Text] [Related]
3. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
[TBL] [Abstract][Full Text] [Related]
4. Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with β-thalassemia.
Spoulou V; Tzanakaki G; Lekka S; Chouliaras G; Ladis V; Theodoridou M
Vaccine; 2011 Jun; 29(27):4435-8. PubMed ID: 21497638
[TBL] [Abstract][Full Text] [Related]
5. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
Findlow H; Borrow R
Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
10. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
[TBL] [Abstract][Full Text] [Related]
11. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
12. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.
Sikkema DJ; Friedman KE; Corsaro B; Kimura A; Hildreth SW; Madore DV; Quataert SA
Clin Diagn Lab Immunol; 2000 Sep; 7(5):764-8. PubMed ID: 10973451
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
[TBL] [Abstract][Full Text] [Related]
16. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
17. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.
Rennels M; King J; Ryall R; Papa T; Froeschle J
Pediatr Infect Dis J; 2004 May; 23(5):429-35. PubMed ID: 15131466
[TBL] [Abstract][Full Text] [Related]
18. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.
Jokhdar H; Borrow R; Sultan A; Adi M; Riley C; Fuller E; Baxter D
Clin Diagn Lab Immunol; 2004 Jan; 11(1):83-8. PubMed ID: 14715549
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
